Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) EBITDA: 2018-2021

Historic EBITDA for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2021 value amounting to -$26.4 million.

  • Black Diamond Therapeutics' EBITDA fell 15.45% to -$26.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$115.0 million, marking a year-over-year decrease of 74.40%. This contributed to the annual value of -$126.6 million for FY2021, which is 90.01% down from last year.
  • According to the latest figures from Q4 2021, Black Diamond Therapeutics' EBITDA is -$26.4 million, which was up 24.81% from -$35.1 million recorded in Q3 2021.
  • Black Diamond Therapeutics' EBITDA's 5-year high stood at -$3.0 million during Q4 2018, with a 5-year trough of -$35.1 million in Q3 2021.
  • Over the past 3 years, Black Diamond Therapeutics' median EBITDA value was -$12.9 million (recorded in 2020), while the average stood at -$16.8 million.
  • Data for Black Diamond Therapeutics' EBITDA shows a maximum YoY slumped of 235.30% (in 2020) over the last 5 years.
  • Quarterly analysis of 4 years shows Black Diamond Therapeutics' EBITDA stood at -$3.0 million in 2018, then slumped by 224.20% to -$9.9 million in 2019, then slumped by 131.77% to -$22.9 million in 2020, then decreased by 15.45% to -$26.4 million in 2021.
  • Its EBITDA stands at -$26.4 million for Q4 2021, versus -$35.1 million for Q3 2021 and -$30.6 million for Q2 2021.